Shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Rating) fell 6.4% during trading on Monday . The stock traded as low as $0.78 and last traded at $0.82. 161,207 shares changed hands during mid-day trading, a decline of 20% from the average session volume of 200,444 shares. The stock had previously closed at $0.88.
Cyclerion Therapeutics Stock Performance
The company has a market cap of $35.66 million, a PE ratio of -0.75 and a beta of 2.05. The company's 50-day simple moving average is $0.60 and its 200 day simple moving average is $0.71.
Get
Cyclerion Therapeutics alerts:
Cyclerion Therapeutics (NASDAQ:CYCN – Get Rating) last issued its quarterly earnings results on Thursday, November 3rd. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.11. Cyclerion Therapeutics had a negative net margin of 2,551.69% and a negative return on equity of 149.84%. Analysts forecast that Cyclerion Therapeutics, Inc. will post -1.16 EPS for the current year.
Hedge Funds Weigh In On Cyclerion Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Mackenzie Financial Corp purchased a new position in Cyclerion Therapeutics in the 1st quarter valued at approximately $28,000. Prudential Financial Inc. acquired a new stake in shares of Cyclerion Therapeutics in the 2nd quarter valued at $29,000. Jane Street Group LLC acquired a new stake in shares of Cyclerion Therapeutics in the 2nd quarter valued at $32,000. Prelude Capital Management LLC raised its holdings in shares of Cyclerion Therapeutics by 29.2% in the 1st quarter. Prelude Capital Management LLC now owns 100,255 shares of the company's stock valued at $111,000 after purchasing an additional 22,672 shares in the last quarter. Finally, Trustcore Financial Services LLC raised its holdings in shares of Cyclerion Therapeutics by 47.7% in the 1st quarter. Trustcore Financial Services LLC now owns 292,645 shares of the company's stock valued at $325,000 after purchasing an additional 94,539 shares in the last quarter. Hedge funds and other institutional investors own 48.34% of the company's stock.
About Cyclerion Therapeutics
(Get Rating)
Cyclerion Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults.
Featured Articles
- Get a free copy of the StockNews.com research report on Cyclerion Therapeutics (CYCN)
- CrowdStrike Selloff: It's Time For Investors to Strike
- Pure Storage is a Steady Eddie Growing Storage Play
- Tesla Shares Are Sliding, Here's Why
- Insiders And Institutions Buy Fastenal, An Aristocrat To Be
- Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
